Friday, 23 Aug 2019

You are here

RheumNow Podcast – Prevalence of Methotrexate Toxicities (6.28.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

  1. Metanalysis of 3954 studies, 20 RCTs examined MTX toxicity and found the prevalence of alopecia to be 1- 4.9% and the prevalence of stomatitis to be between 5.7-8% https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.23999
  2. A Western Norway study of GCA (1972–2012) compared 792 GCA (528 Bx-verified) to 2577 matched controls. There were no differences in overall survival (p=0.41). GCA had higher risk of CV death (HR 1.31) but lower risk of cancer deaths (HR 0.56). https://t.co/oBx2kBTyrZ
  3. 795 RA patients from the GIRRCS cohort 3 year study found that maintaining remission reduced the incidence of subclinical atherosclerosis by three-quarters (OR = 0.25; P = .001). (87% were on MTX; 60% on biologics) #EULAR2019 ABST# OP0090 https://t.co/RvRcXsDnKs
  4. Study of 1224 SLE pts found 7% with neuropathies (PNS) w/ 2/3 attributable to SLE. 67% PNS occurred w/in 3 mos of SLE diagnosis. Periph. polyneuropathy was most common (43%). PNS pts were older, w/ higher SLEDAI-2K, Sjogrens, livedo, HTN, DM. https://t.co/G7l2GGbmgR
  5. 2,899 RA and 112,571 OA pts had THA or TKA. RA had more infections (HR 1.29;1.03-1.61) post THA/TKA, but fewer VTE (HR 0.60; 0.26-0.98) post TKA. Biologics in RA had a similar infx risk but more VTE (HR 4.82;1.67-13.9) vs non-biologics. https://www.sciencedirect.com/science/article/abs/pii/S0049017219302811?dgcid=rss_sd_all 
  6. Study of PsA (N = 341) pts starting secukinumab with or without a baseline loading dose of SEC 150 mg, showed equal ACR20 responses at week 16 - 41.2% vs 39.8%. Despite some w/ an earlier response, the SEC loading dose may not be necessary. https://www.ncbi.nlm.nih.gov/pubmed/31228101 
  7. CDC reports a 3-10mos shortage of Aplisol, a PPD product. Another PPD product, Tubersol is available for skin testing. CDC recs to use IGRA blood tests for TST & prioritize TSTs. Switching from PPD to IGRA may result in conversions requiring interpretation https://t.co/eJGOHVCbkO 
  8. "Clinicians should assess test results based on the person's likelihood of infection and risk for progression to TB disease, if infected," according to the CDC. MMWR. 2019;68:552-553.  https://www.cdc.gov/mmwr/volumes/68/wr/mm6824a4.htm
  9. DMARD Success in Myositis-Related Interstitial Lung Disease  
  10. Steroids in GCA and PMR Increase Infectious Risk  
  11. Mortality from Falls in the Elderly   

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.